ELDN Eledon Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1404281 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-6.6%
TTM EPS YoY-586.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-257.1%
ROA-71.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets34.5%
Debt / equity0.00x
Current ratio6.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-5.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $17.76M | $18.23M | $17.20M | $17.49M | $14.97M | $20.28M | $13.53M | $17.93M |
| SG&A expense | $3.91M | $4.64M | $3.98M | $3.99M | $4.10M | $4.46M | $4.43M | $6.77M |
| Operating income | -$21.67M | -$22.87M | -$21.18M | — | -$19.07M | -$24.73M | -$17.96M | — |
| Net income | -$3.93M | -$31.63M | -$39.02M | -$10.45M | -$17.46M | -$11.22M | -$6.50M | -$44.62M |
| EPS (basic) | -0.03 | -0.27 | -0.33 | — | -0.21 | -0.13 | -0.08 | — |
| EPS (diluted) | -0.03 | -0.27 | -0.33 | — | -0.21 | -0.13 | -0.08 | — |
| Weighted avg. shares (diluted) | 114.72M | 113.63M | 112.42M | — | 77.16M | 77.16M | 77.13M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $6.88M | $6.80M | $6.15M | $22.81M | $3.67M | $5.74M | $8.50M | $20.55M |
| Short-term investments | $62.79M | $81.95M | $104.94M | $110.53M | $89.73M | $101.83M | $116.39M | $119.63M |
| Current assets | $73.71M | $93.09M | $113.57M | $135.69M | $96.30M | $111.40M | $127.72M | $143.73M |
| Total assets | $106.64M | $126.09M | $146.67M | $169.01M | $129.86M | $144.91M | $161.31M | $177.41M |
| Current liabilities | $11.70M | $11.79M | $13.46M | $18.34M | $14.30M | $13.72M | $9.19M | $11.58M |
| Total liabilities | $36.83M | $54.06M | $46.21M | $32.23M | $38.80M | $38.88M | $46.73M | $59.27M |
| Shareholders' equity | $30.80M | $33.01M | $44.76M | $81.08M | $35.36M | $50.33M | $58.89M | $62.45M |
| Shares outstanding | 81.44M | 80.89M | 75.85M | 75.43M | 59.88M | 59.88M | 59.88M | 59.79M |
| Cash flow statement | ||||||||
| Operating cash flow | -$18.98M | -$22.68M | -$22.61M | -$14.09M | -$14.48M | -$17.71M | -$16.06M | -$18.99M |
| Investing cash flow | $19.33M | $23.24M | $5.96M | -$20.46M | $12.40M | $14.96M | $3.89M | -$47.38M |
| Financing cash flow | -$271,000 | — | — | $53.69M | $0 | $0 | $115,000 | $80.17M |
| Stock-based compensation | $1.92M | $3.15M | $2.20M | $2.46M | $2.43M | $2.69M | $2.86M | $6.58M |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.